Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Puma Biotechnology, Inc. (PBYI) had Revenue of $230.47M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$230.47M
Net Income	$30.28M
Cost of Goods Sold	$64.40M
Gross Profit	$166.06M
Operating Expenses	$199.50M
Operating Income	$30.97M
Non-Operating Income/Expense	$-6.87M
Pre-Tax Income	$24.10M
Normalized Pre-Tax Income	$24.10M
Income after Taxes	$30.28M
Income from Continuous Operations	$30.28M
Consolidated Net Income/Loss	$30.28M
Normalized Income after Taxes	$30.28M
EBIT	$30.97M
EBITDA	$42.49M
Weighted-Average Shares Outstanding (Basic)	48.65M
Weighted-Average Shares Outstanding (Diluted)	49.10M
Earnings per Share (EPS) (Basic)	$0.62
Earnings per Share (EPS) (Diluted)	$0.62
Balance Sheet Financials
Current Assets	$147.66M
Property, Plant, and Equipment	$0.52M
Long-Term Assets	$65.67M
Total Assets	$213.33M
Current Liabilities	$96.11M
Long-Term Debt	$21.72M
Long-Term Liabilities	$25.10M
Total Liabilities	$121.21M
Common Equity	$92.12M
Tangible Shareholders Equity	$40.99M
Shareholders Equity	$92.12M
Common Shares Outstanding	49.11M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$38.92M
Cash Flow from Investing Activities	$-20.44M
Cash Flow from Financial Activities	$-33.85M
Beginning Cash	$86.68M
End Cash	$71.31M
Increase/Decrease in Cash	$-15.37M
Stock-Based Compensation	$8.24M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.54
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.19
Debt to Equity Ratio	0.73
Gross Margin	72.06%
Operating Margin	13.44%
EBIT Margin	13.44%
EBITDA Margin	18.44%
Pre-Tax Profit Margin	10.46%
Profit Margin	13.14%
Free Cash Flow	$38.86M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	1.08
Inventory Turnover	7.38
Receiveable Turnover	7.20
Days Sales in Receivables	50.70
Return on Equity	32.87%
Return on Tangible Equity	73.86%
Return on Assets	14.19%
Return on Investments	26.60%
Book Value Per Share	$1.88
Free Cash Flow per Share	$0.79
Operating Cash Flow per Share	$0.79

Data from Zacks Investment Research, Inc.